Active booster immunization against diphtheria, tetanus, and pertussis in persons >10 years of age; wound management for the prevention of tetanus.

Vaccine; Vaccine, Inactivated (Bacterial)

Hypersensitivity to diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or any component of the formulation

In general, maternal use of inactivated vaccines is not associated with increased risks to the fetus.
In addition, an increased risk of adverse maternal or fetal outcomes, including miscarriage or major birth defects, has not been observed following maternal use of the Tdap vaccine.

It is not known if this vaccine is present in breast milk.
According to the manufacturer, the decision to continue or discontinue breastfeeding following immunization should consider the risk and the benefits.

Hypoactivity, headache, fatigue, malaise, body pain, myasthenia, chills, increased arm circumference, gastrointestinal symptoms, nausea, pain or erythema or swelling at injection site, myalgia, arthralgia, fever

Catch-up immunization:

IM: 0.5 mL as a 3-dose series at 0, ?4 weeks, and 6 to 12 months later. At least 1 dose should be Tdap; preferably dose 1, with either Td or Tdap appropriate for doses 2 and 3.
Note: For persons who have never received a pertussis-, tetanus-, or diphtheria-containing vaccine.

Booster immunization :

IM: 0.5 mL per dose. Any patient who has not previously received a dose of Tdap should receive a dose of Tdap, regardless of interval since last tetanus- or diphtheria-containing vaccine. A booster dose of either Td or Tdap should be administered every 10 years throughout life.

Tetanus prophylaxis in wound management :

IM: Tetanus prophylaxis in patients with wounds should be based on if the wound is clean or contaminated and the immunization status of the patient, including time from last tetanus-containing vaccine. Wound management includes use of tetanus toxoid and/or tetanus immune globulin (TIG) where appropriate, wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until >10 years after the most recent dose even if they have a wound that is neither clean nor minor.

Booster immunization:

Children >10 years and Adolescents:
IM 0.5 mL as a single routine booster dose at age 11 or 12 years in children who have completed a childhood vaccination series, followed by additional booster doses of either Td or Tdap every 10 years.
Note: If Tdap was given either inadvertently or used as part of catch-up dosing at 7 to 9 years of age, it should not be counted as the adolescent booster dose and the child should still receive a Tdap booster between ages 11 to 12 years. At age 10 years, Tdap doses given as part of catch-up series or DTaP doses given inadvertently may count as the adolescent Tdap dose.

Tetanus prophylaxis in wound management:

Children >7 years and Adolescents: IM 0.5 mL as a single dose.

Refrigerate at 2 to 8 degrees C. Do not freeze.
If the vaccine had froze, please throw away.